Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
EmbarkNeuro logo — Exploring pathways for the personalized treatment of mental...

EmbarkNeuro

Exploring pathways for the personalized treatment of mental health

Founded 2019 United States Oakland, United States 4 employees Biotechnology, Health and Wellness +1

General Information

Company Name EmbarkNeuro
Founded Year 2019
Location United States Oakland, United States
Employees 4
Industries Biotechnology, Health and Wellness, Life Sciences
Social

BounceWatch is an independent company data service, not affiliated with EmbarkNeuro. To contact EmbarkNeuro, visit embarkneuro.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does EmbarkNeuro compare?

A PDF of EmbarkNeuro and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting EmbarkNeuro soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About EmbarkNeuro

EmbarkNeuro is a neuroscience-focused biotech startup, founded in 2019 and headquartered in the United States. It is a portfolio company of Aditum Bio, a biotech investment firm co-founded by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. The company's slogan, "Exploring pathways for the personalized treatment of mental health," reflects its focus on mental health treatment. EmbarkNeuro is currently evaluating a Phase II asset in patients with major depressive disorder. The company's formation followed the in-licensing of a selective vasopressin 1b receptor (V1b) antagonist (ANC-501) from Taisho Pharmaceutical Co., Ltd. The company's approach is patient-centric, collaborative, curious, and courageous. As of now, there is no information available about the last investment or the investors involved. EmbarkNeuro operates in the biotechnology, health and wellness, and life sciences industries. Overall, EmbarkNeuro's strategic focus on personalized mental health treatments and its relation to industry-leading figures such as Joe Jimenez and Dr. Mark Fishman positions the company as an innovative player in the biotech landscape.

Business keywords: neuroscience, biotech, investing, mental health, personalized treatment, phase II clinical trial, V1b antagonist, biomarker, depression, patient-centric, collaborative, ANC-501, stress response system, drug development, Taisho Pharmaceutical Co., Ltd.

No funding data available for EmbarkNeuro yet.

EmbarkNeuro Alternatives & Competitors

View All Alternatives
EmbarkNeuro vs
X4 Pharmaceuticals
X4 Pharmaceuticals United States

Enabling a better future for people with rare immune disorders

Post-IPO Debt
137 employees
Biotechnology, Health Care
EmbarkNeuro vs
Azevan Pharmaceuticals
Azevan Pharmaceuticals

Innovative therapies for stress, mood, and behavior disorders

Venture round
5 employees
Biotechnology, Health Care
EmbarkNeuro vs
Spiritus Bioscience
Spiritus Bioscience

Improve existing strategies of drug delivery for some of the most pressing mental health issues of o...

Venture round
3 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About EmbarkNeuro

Exploring pathways for the personalized treatment of mental health
EmbarkNeuro was founded in 2019.
EmbarkNeuro is headquartered in Oakland, United States.
EmbarkNeuro operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on neuroscience, biotech, investing and mental health.
EmbarkNeuro has approximately 4 employees.
Top alternatives and competitors to EmbarkNeuro include X4 Pharmaceuticals, Azevan Pharmaceuticals, Spiritus Bioscience, Kinarus Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EmbarkNeuro and X4 Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EmbarkNeuro, https://bouncewatch.com/company/embarkneuro, updated 2 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes